A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination with Venetoclax in Subjects with Relapsed or Refractory Haematologic Malignancies

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

Diagnosis of any of the following hematologic malignancies and histologically proven based on criteria established by the World Health Organization (WHO) as documented by medical records: o non-Hodgkin lymphoma o Richter syndrome o CLL/small lymphocytic lymphoma (SLL) o T-cell lymphoma o multiple myeloma (MM)  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.  Must have received at least 2 prior lines of therapy for the treatment of current histology; there are no treatment options available known to provide clinical benefit. Refer to National Comprehensive Cancer Network (NCCN) guidelines of each respective histology for guidance.

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 17-0900

More information available at ClinicalTrials.gov: NCT03218683

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers